Unique ID issued by UMIN | UMIN000013594 |
---|---|
Receipt number | R000015881 |
Scientific Title | Establishment of treatment regimen to eradicate H. pylori infection in patients who failed 1st-line and 2nd-line therapy. |
Date of disclosure of the study information | 2014/04/01 |
Last modified on | 2020/04/06 13:41:40 |
Establishment of treatment regimen to eradicate H. pylori infection in patients who failed 1st-line and 2nd-line therapy.
Alternative eradicate therapy for H. pylori infection.
Establishment of treatment regimen to eradicate H. pylori infection in patients who failed 1st-line and 2nd-line therapy.
Alternative eradicate therapy for H. pylori infection.
Japan |
Helicobacter pylori-associated gastritis
Gastroenterology |
Others
NO
Establish a treatment regimen to eradicate H. pylori infection in patients who failed conventional therapy.
Safety,Efficacy
Exploratory
Pragmatic
Not applicable
eradication rate
side effects
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Medicine |
Treat the patients who failed conventinal eradication therapy using sitafloxasin containing regimen
18 | years-old | <= |
Not applicable |
Male and Female
patients who was diagnosed as infected-with H. pylori
who did not agree
100
1st name | Shinsaku |
Middle name | |
Last name | Fukuda |
Hirosaki University Graduate School of Medicine
Gastroenterology
036-8562
5 Zaifu-cho, Hirosaki
0172-39-5053
tsimo_hki@hotmail.com
1st name | Tadashi |
Middle name | |
Last name | Shimoyama |
Hirosaki University Graduate School of Medicine
Gastroenterology
036-8562
5 Zaifu-cho, Hirosaki
0172-39-5053
tsimo@hirosaki-u.ac.jp
Hirosaki University Graduate School of Medicine
Hirosaki University Graduate School of Medicine
Self funding
Japan
Hirosaki University Graduate School of Medicine
5 Zaifu-cho, Hirosaki 06-8562, Japan
0172-39-5053
tsimo@hirosaki-u.ac.jp
NO
弘前大学医学部付属病院
2014 | Year | 04 | Month | 01 | Day |
https://onlinelibrary.wiley.com/journal/15235378
Unpublished
https://onlinelibrary.wiley.com/journal/15235378
50
The eradication rate of PCAB-AMOX-STFX was 85.7% (42/49; 95% CI, 75.9-95.5%) by intention-to-treat analysis and 87.5% (42/48; 78.4-96.9%) by per protocol analysis. Eradication was unsuccessful in one of two patients whose strains had low sensitivity to AMOX and three patients whose strains were resistant to STFX In contrast, eradication therapy was successful in 13 patients infected with strains which were sensitive to both AMOX and STFX.
2020 | Year | 04 | Month | 06 | Day |
Delay expected |
not accepted.
H. pylori-positive patients who had failed both first-line therapy (PPI or VPZ + AMOX + clarithromycin) and second-line therapy (PPI or VPZ + AMOX + metronidazole) were enrolled into the study.
Prior to the third-line therapy, patients underwent endoscopy to obtain H. pylori strains to test the susceptibility to antibiotics if they agreed.
None.
The eradication rate of PCAB-AMOX-STFX was 85.7% (42/49; 95% CI, 75.9-95.5%) by intention-to-treat analysis and 87.5% (42/48; 78.4-96.9%) by per protocol analysis. H. pylori was isolated from 19 patients before starting the triple therapy of PCAB, AMOX and STFX. Eradication was unsuccessful in one of two patients whose strains had low sensitivity to AMOX. In contrast, eradication therapy was successful in 13 patients infected with strains which were sensitive to both AMOX and STFX.
Completed
2013 | Year | 07 | Month | 09 | Day |
2013 | Year | 09 | Month | 01 | Day |
2013 | Year | 09 | Month | 01 | Day |
2017 | Year | 09 | Month | 30 | Day |
2017 | Year | 12 | Month | 30 | Day |
2017 | Year | 12 | Month | 30 | Day |
2018 | Year | 09 | Month | 30 | Day |
2014 | Year | 04 | Month | 01 | Day |
2020 | Year | 04 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000015881
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |